

LIFELINE THERAPEUTICS, INC.
Form 8-K
January 19, 2006

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 17, 2006

Lifeline Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Colorado

000-30489

84-1097796

(State or other jurisdiction
of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

6400 South Fiddler s Green Circle, Suite 1970, Englewood, CO 80111
(Address of principal executive offices) (Zip Code)

Registrant s telephone number, including area code: (720) 488-1711

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure

From January 17, 2006 until January 20, 2006, in connection with the release of the article in the scientific journal *Free Radical Biology & Medicine* (Jan. 15, 2006) entitled "The induction of human superoxide dismutase and catalase in vivo: A fundamentally new approach to antioxidant therapy," Stephen K. Onody, Chief Executive Officer of Lifeline Therapeutics, Inc. (the Company), and Joe M. McCord, Ph.D., Director of Science for the Company, are meeting with members of the investment community, and will be guests on various radio interviews.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: January 18, 2006

LIFELINE THERAPEUTICS, INC.

By: /s/ Stephen K. Onody
Stephen K. Onody
Chief Executive Officer